Clinical Trials Logo

Ataxia Telangiectasia clinical trials

View clinical trials related to Ataxia Telangiectasia.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT04605523 Enrolling by invitation - Clinical trials for Ataxia Telangiectasia

Neurofilament Light- Chain in Ataxia Telangiectasia

Start date: February 1, 2020
Phase:
Study type: Observational

Ataxia telangiectasia (A-T) is a rare autosomal recessive neurodegenerative disorder characterized by progressive cerebellar ataxia, immunodeficiency, chromosomal instability, and cancer susceptibility. Currently there are no curative therapy options. The clinical presentation of the disease has a wide variety is linked to the proven mutation, immunological status and residual ATM kinase activity. Apart from these prognostic markers, hardly any biomarker to predict disease course is available. Aim of the present proposal is to evaluate serum concentrations of neurofilament - light chain in the serum of whole blood as biomarker of neurodegeneration prospectively. In addition to that, the investigators will examine the evolution of neurofilament - light chain longitudinally by blood samples from our biobank as well as the concentration of neurofilament - light chain in cerebrospinal fluid (CSF) of affected A-T patients from our biobank. As in other neurodegenerative disorders and ataxias, the investigators expect that neurofilament- light chain levels are increased in the A-T cohort and correlated to the neurological status of A-T patients evaluated by means of AT-score.